Reducing antipsychotic use in nursing homes is an ongoing priority for clinicians and their teams. A study in the June issue of JAMDA suggests that substantial improvements in the use of these drugs may be achieved through targeted, collaborative...
Patrick Connole A new study in JAMDA provides information on how skilled nursing facilities (SNFs) can continue to manage the prescription of antipsychotics at a time practitioners are using greater caution than ever in how they distribute such...
While practitioners use great caution when prescribing antipsychotics for nursing home (NH) residents with dementia, implementing evidence-based antipsychotic prescribing practices can be challenging. A new study in the November issue of JAMDA...
After years of criticism, nursing homes have curbed administering antipsychotics, but some providers are questioning whether the across-the-board cuts are preventing some seniors from getting needed medications.
Falls are a serious threat to the health and safety of older Americans and can have consequences ranging from bruises to head trauma. Now a new study, published in JAMDA – The Journal of Post-Acute and Long-Term Care Medicine , suggests that the...
The CMS says it has surpassed its goal for reducing the use of antipsychotic medications in nursing homes. Patient advocates, however, are expressing skepticism over the claim.
Nursing homes in the United States care for increasing numbers of people with dementia, yet many lack access to geriatric psychiatrists, behavioral neurologists and other specialists who may help manage symptoms associated with dementia, including...
“Even very modest efforts at education and problem-solving can go a long way to improving care for people with dementia and reducing bad habits in the care of these patients,” said Jonathan Evans, MD, MPH, CMD. “There is no question there is a...
The studies that led to warnings from health regulators against prescribing antipsychotics to elderly patients with dementia were biased, and there is actually no significant increase in risk of death linked to the drugs, according to a study in...
The $3.83B company on August 6, 2015 announced the publication of new data from its ongoing open-label safety extension study, the -015 Study, with NUPLAZID™ in patients with Parkinson’s disease psychosis (PDP) in the July 31 online issue of the...
